Feedback (LON:FDBK), a medical imaging software firm, is teaming up with the University of Texas to examine the potential clinical application of the company’s TexRAD tumour-imaging technology.
Specifically, experts in the MD Anderson Cancer Centre in Houston will look at how TexRAD derives ‘textures’ from routine diagnostic images, i.e. CT scans, of patients with kidney and adrenal cancer.
The study will include around 400 patients, although the results will not be used to influence or guide the treatment regimes.
Instead, the findings will help to strengthen the evidence base of TexRAD as an up and coming tumour texture heterogeneity analysis software.
Prof. Haesun Choi, who will lead the study, said limitations of the size-based traditional evaluation of solid tumours have been well recognised.
“More reliable user-friendly biomarkers that can reflect the tumour response and that can be used in risk-stratification are needed.
“Analysing the tumour heterogeneity on CT images may provide insights of tumours that may be useful in evaluating the tumour response.”
Earlier this week, Feedback signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust.
Under the deal, experts will investigate the potential future clinical application of Feedback's TexRAD on CT image data of patients with kidney stones.
Feedback shares added 1% to 2.1p this morning.